Results for 'approval'
Rebecca Previs
Tumor-Agnostic Therapies and the Future of HER2 in Oncology
Labcorp, Rebecca Previs, Heidi Ko, HER2, NGS, precision oncology, tumor agnostic, breast cancer, gastric cancer, biomarker, ERBB2, IHC, FISH, biomarker
What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types.
Jun 8th • 20 mins listen
Michael Pietrack
Season 1, Episode 18: Challenges Facing the Pharma Universe with Jack West
In this episode of the Pharmaverse podcast, host Michael Pietrack interviews Jack West, the VP of Clinical Development at Summit Therapeutics. They discuss Jack's transition from being a practicing oncologist to working in the pharmaceutical industry, the importance of collaborations with pharm…
Sep 9th • 35 mins listen
Michael Pietrack
Season 2, Episode 21: A Century of X-Rays with Margaret Yu
In this powerful episode of the Pharmaverse Podcast, host Michael Pietrack sits down with Dr. Margaret Yu, Chief Medical Officer at ARTBIO, an oncology company leading the charge in Radioligand Therapy (RLT) to revolutionize cancer care. Dr. Yu unpacks the 130-year history of radiation in medi…
Oct 27th • 20 mins listen
The Oncology Nursing Podcast
Oncology Clinical Trials and Drug Development
ONS member Moe Schwartz, PharmD, BCOP, professor of pharmacy practice in the James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio and member of the Cincinnati Tri-State ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss cancer drug…
Oct 16th • 38 mins listen
The Oncology Nursing Podcast
How Biosimilars Could Impact the Future of Cancer Care
Rowena Schwartz, PharmD, BCOP, associate professor of pharmacy at the University of Cincinnati, joins Deborah Struth, MSN, RN, ONS research associate, to discuss the rapid emergence of biosimilar products on the market and how they’ll impact the treatment of cancer. Learn more about what bio…
May 7th • 16 mins listen
The Oncology Nursing Podcast
Oncology Pharmacology 2023: Today’s Treatments and Tomorrow’s Breakthroughs
CDER, FDA, Nurses, biomarker, immunomodulatory
Highlights From Today’s Episode “Full approval through the Center for Drug Evaluation and Research (CDER) and FDA means that those drugs have gone through the laboratory testing, human clinical trial testing, and very extensive clinical trials to make sure that they are effective and th…
Mar 30th • 53 mins listen